Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqBDLSF 20 5-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates BDLSF with a GF Score™ of 20/100 and a GF Value™ of $0.15. The stock has 3 warning signs investors should review. Among 33 Medical Diagnostics & Research companies, Inoviq ranks worse than 3030300% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq 5-Year Dividend Growth Rate Related Terms
BDLSF vs TMO, DHR, NTRA: 5-Year Dividend Growth Rate Comparison
For the Diagnostics & Research subindustry, Inoviq's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq 5-Year Dividend Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's 5-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Inoviq's 5-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Dividend Growth Rate of 0.00% mean?
Inoviq (BDLSF) has a 5-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 5-Year Dividend Growth Rate is the company's five-year average growth of dividend payout. View historical data on Inoviq and its competitors. According to the industry distribution chart, Inoviq ranks #999999 out of 33 companies in the Medical Diagnostics & Research industry.
Is Inoviq's 5-Year Dividend Growth Rate too high?
Inoviq's current 5-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Inoviq ranks #999999 out of 33 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Inoviq has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Inoviq's 5-Year Dividend Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #999999 out of 33 companies for 5-Year Dividend Growth Rate. This places Inoviq in the lower half of its industry. The industry median 5-Year Dividend Growth Rate is 11.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Dividend Growth Rate for a Medical Diagnostics & Research company?
The median 5-Year Dividend Growth Rate among Medical Diagnostics & Research companies is 11.10, based on 33 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Dividend Growth Rate mean?
A high 5-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year Dividend Growth Rate is the company's five-year average growth of dividend payout. View historical data on Inoviq and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Dividend Growth Rate is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current 5-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Inoviq (BDLSF) has a current 5-Year Dividend Growth Rate of 0.00%. The stock's GF Value™ is $0.15, compared to a current price of $0.12 — trading 20% below its estimated fair value. The current 5-Year Dividend Growth Rate is 0.00%. Inoviq's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Dividend Growth Rate calculated?
5-Year Dividend Growth Rate is calculated from a company's financial statements. For Inoviq (BDLSF), the current 5-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (BDLSF) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of $0.12 is trading 20% below its estimated GF Value™ of $0.15.
Key valuation signals for BDLSF:
5-Year Dividend Growth Rate: 0.00%
GF Value™: $0.15 vs. price of $0.12 (20% below fair value)
No single metric tells the full story. See the BDLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
20GF Score
Get the complete analysis for BDLSF
5-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDLSF has been successfully added to your 
